Article info
Cystic fibrosis
Original article
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
- Correspondence to Dr Nataliya Volkova, Vertex Pharmaceuticals Incorporated, Boston MA 02210, USA; Nataliya_Volkova{at}vrtx.com
Citation
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
Publication history
- Received April 11, 2017
- Revised March 23, 2018
- Accepted April 9, 2018
- First published May 10, 2018.
Online issue publication
July 13, 2018
Article Versions
- Previous version (10 May 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/